Study of combination therapy before surgery for ER+/HER2+ breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old who has been newly diagnosed with breast cancer.
- Your breast cancer must test positive for HER2 and have at least 10% ER (estrogen receptor) positive cells.
- The tumor must be larger than 2 cm or have spread to lymph nodes, but not to distant parts of the body (stage IV).
- You must have good organ function, including normal blood counts, liver and kidney tests, and a heart pump reading (LVEF) of 55% or higher.
- You cannot have had other cancer treatments or major surgery in the past 4 weeks, and must not be pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests whether adding pyrotinib to trastuzumab after surgery can reduce breast cancer coming back in people with HER2-positive, early-stage breast cancer. It may help some patients by improving treatment effectiveness, but it also requires meeting specific heart, lab, and health criteria.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
This trial tests whether a combination of targeted therapies and hormone therapy can shrink triple-positive breast cancer before surgery. It is for women with stage II or III breast cancer that has not yet been treated.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.